Alemtuzumab
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Alemtuzumab |
| DrugBank ID | DB00087 |
| Brand Names (EU) | Lemtrada |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 96.51% |
Approved Indication (EMA)
Lemtrada is indicated for adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | relapsing-remitting multiple sclerosis | 96.51% | DL |
| 2 | hepatic infarction | 94.44% | DL |
| 3 | syndrome with combined immunodeficiency | 93.73% | DL |
| 4 | hepatic veno-occlusive disease | 93.14% | DL |
| 5 | kidney pelvis sarcomatoid transitional cell carcinoma | 93.09% | DL |
| 6 | infiltrating bladder urothelial carcinoma sarcomatoid variant | 92.93% | DL |
| 7 | prostatic urethra urothelial carcinoma | 92.85% | DL |
| 8 | renal pelvis papillary urothelial carcinoma | 92.81% | DL |
| 9 | peliosis hepatis | 92.20% | DL |
| 10 | hemophagocytic syndrome associated with an infection | 89.93% | DL |
| 11 | acquired hemophagocytic lymphohistiocytosis associated with malignant disease | 89.93% | DL |
| 12 | stone in bladder diverticulum | 87.56% | DL |
| 13 | non-severe combined immunodeficiency | 87.56% | DL |
| 14 | chromhidrosis | 87.39% | DL |
| 15 | severe combined immunodeficiency (disease) | 86.73% | DL |
| 16 | cervical neuroblastoma | 86.71% | DL |
| 17 | schwannoma of jugular foramen | 86.64% | DL |
| 18 | benign neoplasm of tongue | 86.42% | DL |
| 19 | benign neoplasm of hypopharynx | 86.29% | DL |
| 20 | benign neoplasm of buccal mucosa | 86.27% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.